A Phase II Randomized Study of Paclitaxel Alone or Combined with Pelareorep with or without Avelumab in Metastatic Hormone Receptor–Positive Breast Cancer: The BRACELET-01/PrE0113 Study
The addition of Pel to Pac was associated with increased toxicity, expanded peripheral T-cell clones, and numerically increased the ORR and progression-free survival compared with Pac; Pac/Pel/Ave further increased toxicity and blunted T-cell responses without obvious increase in efficacy. Investigation of the Pac/Pel combination warrants consideration with careful attention to acute toxicity.
Authors
- Richard Trauger
- Elisa Krill-Jackson
- Thomas Charles Heineman (ORCID: https://orcid.org/0000-0003-4500-5676)
- Alberto J. Montero (ORCID: https://orcid.org/0000-0002-8221-8120)
- Antonio C. Wolff (ORCID: https://orcid.org/0000-0003-3734-1063)
- Fengmin Zhao (ORCID: https://orcid.org/0000-0001-9826-3703)
- Kendrith M. Rowland (ORCID: https://orcid.org/0000-0003-0640-6733)
- Amy S. Clark (ORCID: https://orcid.org/0000-0002-3685-6535)
- Sagar Sardesai (ORCID: https://orcid.org/0000-0002-2688-0486)
- Kathy D. Miller (ORCID: https://orcid.org/0000-0002-7125-883X)
- Patrick M. Dillon (ORCID: https://orcid.org/0000-0003-0622-725X)
- Jason Incorvati
- Matt Coffey (ORCID: https://orcid.org/0000-0002-7211-829X)
- Paula Klein (ORCID: https://orcid.org/0009-0002-6017-2712)
- Carla I. Falkson (ORCID: https://orcid.org/0000-0003-2370-6818)
Institutions
- Indiana University Health (US)
- Fox Chase Cancer Center (US)
- Carle Foundation Hospital (US)
- Johns Hopkins University (US)
- University of Miami (US)
- Urbana University (US)
- University of Rochester Medical Center (US)
- ECOG-ACRIN Cancer Research Group (US)
- University of Miami Health System (US)
- Ohio University (US)
- Indiana Cancer Consortium (US)
- Dana-Farber Cancer Institute (US)
- University Hospitals Seidman Cancer Center (US)
- Tisch Hospital (US)
- Dana-Farber/Harvard Cancer Center (US)
- VLP Biotech (United States) (US)
- University of Virginia Cancer Center
- Indiana University School of Medicine
- University of Virginia (US)
- The Ohio State University (US)
- University of Rochester (US)
- Indiana University – Purdue University Indianapolis (US)
- University of Baltimore (US)
- University of Pennsylvania (US)
- Oncolytics Biotech (Canada) (CA)
- Philadelphia University (US)
- Icahn School of Medicine at Mount Sinai (US)
Publication Details
- Journal
- Clinical Cancer Research
- Published
- 2025-04-29
- DOI
- https://doi.org/10.1158/1078-0432.ccr-24-2701
- Citations
- 8
- Primary Topic
- Advanced Breast Cancer Therapies
- Type
- article
- Field-Weighted Citation Impact
- 12.15
Funders
- Pfizer
- Oncolytics Biotech